33296042|t|Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the alpha2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain.
33296042|a|BACKGROUND: Availability of the alpha2C-adrenoceptor (alpha2C-AR) positron emission tomography (PET) tracer, [11C]ORM-13070, and the alpha2C-AR antagonist ORM-12741 allows probing of the roles of this G-protein coupled receptor subtype in brain function, both in healthy humans and in patients with various brain disorders. This translational study employed [11C]ORM-13070 autoradiography and PET to determine alpha2C-AR occupancy by ORM-12741 in rat and human brain, respectively. RESULTS: ORM-12741 has high affinity (Ki: 0.08 nM) and potent antagonist activity (Kb: 0.04 nM) as well as selectivity (Ki estimates for the human alpha2A-AR and alpha2B-AR were 8.3 nM and 0.8 nM, respectively) for the human alpha2C-AR subtype. [11C]ORM-13070 had highest uptake in the basal ganglia of rat and human brain. Pretreatment with ORM-12741 inhibited [11C]ORM-13070 binding in rat striatum in a time- and dose-dependent manner at 10 and 50 microg/kg (s.c.) with an EC50 estimate of 1.42 ng/mL in rat plasma, corresponding to protein-free drug concentration of 0.23 nM. In the living human brain, time- and dose-related alpha2C-AR occupancy was detected with EC50 estimates of 24 ng/mL and 31 ng/mL for the caudate nucleus and putamen, respectively, corresponding to protein-free concentrations in plasma of 0.07 nM and 0.1 nM. Modelling-based maximum alpha2C-AR occupancy estimates were 63% and 52% in the caudate nucleus and the putamen, respectively. CONCLUSIONS: ORM-12741 is a selective alpha2C-AR antagonist which penetrates the rat and human brain to occupy alpha2C-ARs in a manner consistent with its receptor pharmacology. Trial registration number and date of registration: ClinicalTrial.cov NCT00829907. Registered 11 December 2008. https://clinicaltrials.gov/ .
33296042	31	44	11C]ORM-13070	Chemical	MESH:C000598340
33296042	82	102	alpha2C-adrenoceptor	Gene	152
33296042	114	123	ORM-12741	Chemical	MESH:C000588919
33296042	174	177	rat	Species	10116
33296042	182	187	human	Species	9606
33296042	227	247	alpha2C-adrenoceptor	Gene	152
33296042	249	259	alpha2C-AR	Gene	152
33296042	305	318	11C]ORM-13070	Chemical	MESH:C000598340
33296042	328	338	alpha2C-AR	Gene	152
33296042	350	359	ORM-12741	Chemical	MESH:C000588919
33296042	466	472	humans	Species	9606
33296042	480	488	patients	Species	9606
33296042	502	517	brain disorders	Disease	MESH:D001927
33296042	554	567	11C]ORM-13070	Chemical	MESH:C000598340
33296042	605	615	alpha2C-AR	Gene	152
33296042	629	638	ORM-12741	Chemical	MESH:C000588919
33296042	642	645	rat	Species	10116
33296042	650	655	human	Species	9606
33296042	686	695	ORM-12741	Chemical	MESH:C000588919
33296042	818	823	human	Species	9606
33296042	824	834	alpha2A-AR	Gene	150
33296042	839	849	alpha2B-AR	Gene	151
33296042	896	901	human	Species	9606
33296042	902	912	alpha2C-AR	Gene	152
33296042	923	936	11C]ORM-13070	Chemical	MESH:C000598340
33296042	980	983	rat	Species	10116
33296042	988	993	human	Species	9606
33296042	1019	1028	ORM-12741	Chemical	MESH:C000588919
33296042	1040	1053	11C]ORM-13070	Chemical	MESH:C000598340
33296042	1065	1068	rat	Species	10116
33296042	1184	1187	rat	Species	10116
33296042	1271	1276	human	Species	9606
33296042	1307	1317	alpha2C-AR	Gene	152
33296042	1539	1549	alpha2C-AR	Gene	152
33296042	1654	1663	ORM-12741	Chemical	MESH:C000588919
33296042	1679	1689	alpha2C-AR	Gene	152
33296042	1722	1725	rat	Species	10116
33296042	1730	1735	human	Species	9606
33296042	Cotreatment	MESH:C000588919	MESH:C000598340
33296042	Negative_Correlation	MESH:C000588919	152
33296042	Association	MESH:D001927	152
33296042	Association	MESH:C000598340	MESH:D001927
33296042	Association	MESH:C000588919	MESH:D001927
33296042	Negative_Correlation	MESH:C000598340	152
33296042	Negative_Correlation	MESH:C000588919	150
33296042	Negative_Correlation	MESH:C000588919	151

